News

Keros Therapeutics: Interesting Early Data From A Promising Molecule (Downgrade) (KROS)

3 Mins read

In April, I covered Keros Therapeutics, Inc. (NASDAQ:KROS), and found it interesting. Keros had three published datasets from three clinical-stage programs. The stock had a short rally after my coverage, then went down, took another small leap, and then went down

Response summary

RP2D Patients

All evaluable patients

HTB evaluable patients

Overall Erythroid Response (HI-E or TI) n (%)

19/37 (51.4)

11/22 (50)

IWG 2006 HI-E, n (%)

19/37 (51.4)

11/22 (50)

TI ≥8 weeks, n (%)

11/26 (42.3)

9/22 (40.9)

RS+, n (%)

8/19 (42.1)

6/17 (35.3)

Non-RS, n (%)

3/7 (42.9)

3/5 (60)

Read the full article here

Related posts
News

Super Micro Computer: The Music’s Still Playing - But I’m Already Out (NASDAQ:SMCI)

1 Mins read
This article was written by Follow I’m passionate about finance and investing, focusing on business analysis, fundamental analysis, valuation, and long-term growth,…
News

Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript

1 Mins read
Talphera, Inc. (NASDAQ:TLPH) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Raffi Asadorian – CFOVincent Angotti –…
News

10 Companies To Announce Dividend Increases In First Half Of April

1 Mins read
This article was written by Follow I’m an individual investor looking to grow my wealth over the long term. I’ve tried many…
Get The Latest News

Subscribe to get the top fintech and
finance news and updates.

Leave a Reply

Your email address will not be published. Required fields are marked *